These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT. Alexander JH; Harrington RA Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986 [TBL] [Abstract][Full Text] [Related]
27. Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab. Mascelli MA; Kleiman NS; Marciniak SJ; Damaraju L; Weisman HF; Jordan RE Am Heart J; 2000 Apr; 139(4):696-703. PubMed ID: 10740154 [TBL] [Abstract][Full Text] [Related]
28. Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future. De Luca G; Savonitto S; van't Hof AW; Suryapranata H Drugs; 2015 Jul; 75(11):1229-53. PubMed ID: 26177890 [TBL] [Abstract][Full Text] [Related]
29. The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. Sabatine MS; Jang IK Am J Med; 2000 Aug; 109(3):224-37. PubMed ID: 10974186 [TBL] [Abstract][Full Text] [Related]
30. The role of eptifibatide in patients undergoing percutaneous coronary intervention. Zeymer U Expert Opin Pharmacother; 2007 Jun; 8(8):1147-54. PubMed ID: 17516878 [TBL] [Abstract][Full Text] [Related]
31. IIb's are not IIb's. Kereiakes DJ; Runyon JP; Broderick TM; Shimshak TM Am J Cardiol; 2000 Apr; 85(8A):23C-31C. PubMed ID: 10793177 [TBL] [Abstract][Full Text] [Related]
32. Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes. Harrington RA Am Heart J; 1999 Oct; 138(4 Pt 2):276-86. PubMed ID: 10502233 [TBL] [Abstract][Full Text] [Related]
33. Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization. Dangas G; Colombo A Am Heart J; 1999 Jul; 138(1 Pt 2):S16-23. PubMed ID: 10385787 [TBL] [Abstract][Full Text] [Related]
34. Analysis of number needed to treat and cost of platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary interventions and acute coronary syndromes. Bell DM Pharmacotherapy; 1999 Sep; 19(9):1086-93. PubMed ID: 10610016 [TBL] [Abstract][Full Text] [Related]
35. Platelet glycoprotein IIb/IIIa-receptor inhibitors in patients with acute coronary syndromes or undergoing percutaneous coronary interventions: a review. Truong KM; Amankwa K; Kucukarslan S Clin Ther; 2001 Aug; 23(8):1145-65; discussion 1129. PubMed ID: 11558855 [TBL] [Abstract][Full Text] [Related]
36. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial. Deibele AJ; Jennings LK; Tcheng JE; Neva C; Earhart AD; Gibson CM Circulation; 2010 Feb; 121(6):784-91. PubMed ID: 20124127 [TBL] [Abstract][Full Text] [Related]
37. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P; Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315 [TBL] [Abstract][Full Text] [Related]
38. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes. Bolognese L Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721 [TBL] [Abstract][Full Text] [Related]
39. Development of glycoprotein IIb-IIIa antagonists: translation of pharmacodynamic effects into clinical benefit. Schneider DJ; Aggarwal A Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):903-13. PubMed ID: 15500435 [TBL] [Abstract][Full Text] [Related]
40. TARGET versus GUSTO-IV: appropriate use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes and percutaneous coronary intervention. Kandzari DE; Califf RM Curr Opin Cardiol; 2002 Jul; 17(4):332-9. PubMed ID: 12151865 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]